Since CT-proET-1, NT-proSST, and MR-proANP could further predict individuals at risk for future PAD development, they might be used at an early stage to motivate individuals at risk to comply with a healthier lifestyle and guideline recommendations22 to counteract CV-related risk factors. The gene discussed is NR3C2; the disease is peripheral arterial disease.